We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




POC Oral Swab Test to Increase Chances of Pregnancy in IVF

By LabMedica International staff writers
Posted on 13 May 2025

Approximately 15% of couples of reproductive age experience involuntary childlessness. More...

A significant reason for this is the growing trend of delaying family planning, a global shift that is expected to increase in the future. In vitro fertilization (IVF) treatment involves stimulating the woman’s ovaries to mature multiple eggs, which are then retrieved, fertilized with sperm in the lab, and later re-implanted into the uterus. There are two main types of hormone treatments available for egg maturation: biological and synthetic. However, while hormone therapy is essential, it carries risks of severe side effects, sometimes leading to the need for intensive care, and many IVF attempts are unsuccessful. One key factor influencing the success of IVF is the choice of hormone therapy, but healthcare providers often face the challenge of selecting the most effective treatment for each woman. Now, a simple oral swab test conducted before IVF could ensure higher success rates.

To identify the most effective hormone treatment for each individual, researchers at Lund University (Lund, Sweden) turned to genetics. Their study involved 1,466 women undergoing IVF treatment, excluding those with endometriosis or polycystic ovary syndrome (PCOS). Among the participants, 475 were randomly assigned to receive one of two hormone treatments, while the remaining participants served as controls. The researchers focused on a gene involved in fertilization, which regulates the action of follicle-stimulating hormone (FSH), a crucial hormone for egg maturation, and mapped this gene through gene sequencing.

The findings, published in Frontiers in Endocrinology, revealed that women carrying a specific variant of the FSH receptor (FSHR) gene, which regulates FSH activity, responded more favorably to biological hormone treatment. Meanwhile, other women benefited more from synthetic hormone treatments. The researchers believe that by understanding a woman’s genetic profile in advance, the likelihood of successful pregnancies can be significantly increased. However, gene mapping is both expensive and time-consuming. To address this, the researchers have developed a simple oral swab test that can quickly determine the most suitable hormone therapy within an hour, with the results indicated by a color change to pink or yellow, making it easy to interpret.

“Our hope is that this will reduce the risk of suffering for women, increase the number of successful treatments and cut costs for taxpayers. Our goal is for the test to be available by the start of 2026,” said Yvonne Lundberg Giwercman, professor at Lund University who led the research.


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
STI Test
REALQUALITY RQ-SevenSTI
New
Multilevel Whole Blood Calibrator Set
6PLUS1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The U.S. FDA-cleared IntelliSep rapid host response diagnostic represents a breakthrough in sepsis care (Photo courtesy of Cytovale)

Rapid Diagnostic Test Slashes Sepsis Mortality by 39%

Sepsis remains one of the most challenging and fatal conditions in contemporary healthcare, accounting for nearly one-third of all hospital-related deaths in the United States. In emergency departments... Read more

Industry

view channel
Image: The knowledge transfer partnership will further develop technology to rapidly diagnose serious and high-risk infectious diseases (Photo courtesy of Aston University)

Aston University and BG Research Partner to Commercialize Groundbreaking Medical Diagnostic

Technology that can rapidly diagnose high-consequence infectious diseases will take a major step forward towards commercialization, thanks to a new partnership. A Knowledge Transfer Partnership (KTP)... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.